nach oben

Erschienen in:

24.09.2021 | Asthma bronchiale | Übersicht

Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem

Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC)

verfasst von: Prof. Dr. med. Ludger Klimek, Ulrike Förster-Ruhrmann, PD Dr. med. Sven Becker, Dr. med. Adam M. Chaker, Sebastian Strieth, Thomas K. Hoffmann, Prof. Dr. med. Stefan Dazert, Thomas Deitmer, Heidi Olze, Alexander Glien, Prof. Dr. med. Stefan Plontke, Holger Wrede, Prof. Dr. med. Wolfgang W. Schlenter, Hans-Jürgen Welkoborsky, Barbara Wollenberg, Achim G. Beule, Claudia Rudack, Prof. Dr. med. Martin Wagenmann, Prof. Dr. Timo Stöver, Tilman Huppertz, Dr. med. Jan Hagemann, Prof. Dr. med. Claus Bachert

Erschienen in: Allergo Journal | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Auszug

Erstpublikation in Laryngorhinootologie 2020;99:511-27; https://doi.org/10.1055/a-1197-0136 …

Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A et al. Chronic rhinosinusitis in European underestimated disease. A GA²LEN study. Allergy 2011;66:1216-23

Hirsch AG, Stewart WF, Sundaresan AS, Young AJ, Kennedy TL, Scott Greene J et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017;72:274-81

Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology 2019;57:43-8

Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015;70:533-9

Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012;23:3 p preceding table of contents, 1-298

Stuck BA, Beule A, Jobst D, Klimek L, Laudien M, Lell M et al. [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery]. HNO 2018;66:38-74

Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12

Rosenfeld RM. Clinical practice guideline on adult sinusitis. Otolaryngol Head Neck Surg 2007;137:365-77

Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int 2018;27:56-65

10.

Tomassen P, Vandeplas G, Van Zele T, Cardell L-O, Arebro J, Olze H et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137:1449-56.e4

11.

Calus L, Van Zele T, Derycke L, Krysko O, Dutre T, Tomassen P et al. Local inflammation in chronic upper airway disease. Curr Pharm Des. 2012;18:2336-46

12.

Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018;73:1459-69

13.

Philpott CM, Erskine S, Hopkins C, Kumar N, Anari S, Kara N et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res 2018;19:129

14.

Wu D, Bleier BS, Li L, Zhan X, Zhang L, Lv Q et al. Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History. J Allergy Clin Immunol Pract 2018;6:1297-305 e1

15.

Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2018;57:32-42

16.

Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53

17.

Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011;25:205-8

18.

Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015;46:1308-21

19.

De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017;7:22

20.

Seys SF, Scheers H, Van den Brande P, Marijsse G, Dilissen E, Van Den Bergh A et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res 2017;18:39

21.

Zhang Y, Derycke L, Holtappels G, Wang XD, Zhang L, Bachert C et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy 2018;74:131-40

22.

Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9

23.

GINA. Global Strategy for Asthma Management and Prevention (2019 update). www.ginasthma.org2019 Contract No.: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

24.

Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016;6 Suppl 1:S22-209

25.

Pundir V, Pundir J, Lancaster G, Baer S, Kirkland P, Cornet M et al. Role of corticosteroids in Functional Endoscopic Sinus Surgery--a systematic review and meta-analysis. Rhinology 2016;54:3-19

26.

Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 2018;74:273-83

27.

Kirsche H, Klimek L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis: Differentialdiagnostik und Therapie. Hno 2015;63:357-63

28.

Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 2009;29:669-75

29.

Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 2019;74:28-39

30.

Hopkins C, Surda P, Bast F, Hettige R, Walker A, Hellings PW. Prevention of chronic rhinosinusitis. Rhinology 2018;56:307-15

31.

Kilty SJ, Lasso A, Mfuna-Endam L, Desrosiers MY. Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 2018;56:155-7

32.

Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology 2016;54:117-28

33.

Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol.2017;13:425-37

34.

Sanofi-Aventis_Deutschland_GmbH. Dupixent^® 300 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2020: p. 21.

35.

Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009;11:257

36.

Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Adv Immunol 2011;109:159-96

37.

Kaur D, Brightling C. OX40/OX40 ligand interactions in T-cell regulation and asthma. Chest 2012;141:494-9

38.

Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000;191:201-6

39.

Plager DA, Kahl JC, Asmann YW, Nilson AE, Pallanch JF, Friedman O et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One 2010;5:e11450

40.

Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61:1280-9

41.

Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8

42.

Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998;9:745-55

43.

Danielsen A, Tynning T, Brokstad KA, Olofsson J, Davidsson A. Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum. Eur Arch Otorhinolaryngol 2006;263:282-9

44.

Derycke L, Eyerich S, Van Crombruggen K, Pérez-Novo C, Holtappels G, Deruyck N et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PloS one 2014;9:e97581

45.

Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein & cell. 2011;2:604-11

46.

Prussin C, Yin Y, Upadhyaya B. T(H)2 heterogeneity: Does function follow form? J Allergy Clin Immunol 2010;126:1094-8

47.

Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837-42

48.

48. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000;14:279-90

49.

Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14

50.

Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005;175:3463-8

51.

Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25-9

52.

Peters AT, Kato A, Zhang N, Conley DB, Suh L, Tancowny B et al. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2010;125:397-403.e10

53.

Keswani A, Chustz RT, Suh L, Carter R, Peters AT, Tan BK et al. Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps. Allergy 2012;67:25-32

54.

Chong LY, Head K, Hopkins C, Philpott C, Schilder AGM, Burton MJ. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011996

55.

Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol 2010;184:3830-40

56.

Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 2006;65 Suppl 3:iii61-4

57.

Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131-42

58.

Li W, Sun W, Liu L, Yang F, Li Y, Chen Y et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol 2010;185:5056-65

59.

Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 2006;3:e277

60.

Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008;181:557-65

61.

Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Curr Opin Otolaryngol Head Neck Surg 2013;21:23-30

62.

Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015;64:121-30

63.

Lam EPS, Kariyawasam HH, Rana BMJ, Durham SR, McKenzie ANJ, Powell N et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol 2016;137:1514-24

64.

Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38

65.

Reh DD, Wang Y, Ramanathan M, Jr., Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010;24:105-9

66.

Kim D-K, Jin HR, Eun KM, Mo J-H, Cho SH, Oh S et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax 2017;72:635-45

67.

Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90

68.

Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009;23:377-84

69.

Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62

70.

Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J Allergy Clin Immunol 2016;138:1243-51

71.

Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012;129:216-27.e1-6

72.

Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol 2016;138:1253-64

73.

Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, Sewell W et al. Cellular comparison of sinus mucosa vs polyp tissue from a single sinus cavity in chronic rhinosinusitis. Int Forum Allergy Rhinol 2015;5:14-27

74.

Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, Sewell W et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy 2015;45:394-403

75.

Allen JS, Eisma R, LaFreniere D, Leonard G, Kreutzer D. Characterization of the eosinophil chemokine RANTES in nasal polyps. The Annals of otology, rhinology, and laryngology. 1998;107(5 Pt 1):416-20

76.

Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, Bickel CA et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J Allergy Clin Immunol 1996;98:766-80

77.

Meyer JE, Bartels J, Gorogh T, Sticherling M, Rudack C, Ross DA et al. The role of RANTES in nasal polyposis. Am J Rhinol 2005;19:15-20

78.

Davidsson A, Danielsen A, Viale G, Olofsson J, Dell'Orto P, Pellegrini C et al. Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. Acta Otolaryngol 1996;116:604-10

79.

Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R et al. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2008;121:1385-92, 1392.e1-2

80.

Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 2006;61:1275-9

81.

Patadia M, Dixon J, Conley D, Chandra R, Peters A, Suh LA et al. Evaluation of the presence of B-cell attractant chemokines in chronic rhinosinusitis. Am J Rhinol Allergy 2010;24:11-6

82.

Mehuys E, Gevaert P, Brusselle G, Van Hees T, Adriaens E, Christiaens T et al. Self-medication in persistent rhinitis: overuse of decongestants in half of the patients. J Allergy Clin Immunol Pract 2014;2:313-9

83.

Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. Jama 2015;314:926-39

84.

84. Smith TL, Sautter NB. Is montelukast indicated for treatment of chronic rhinosinusitis with polyposis? The Laryngoscope 2014;124:1735-6

85.

Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg 2008;139:682-7

86.

Rondón C, Dávila I, Navarro Pulido AM, Sánchez MC, Montoro J, Matheu V et al. Clinical Management and Use of Health Care Resources in the Treatment of Nasal Polyposis in Spanish Allergy Centers: The POLAR Study. J Investig Allergol Clin Immunol 2015;25:276-82

87.

Wei CC, Adappa ND, Cohen NA. Use of topical nasal therapies in the management of chronic rhinosinusitis. Laryngoscope 2013;123:2347-59

88.

Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AGM. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011991

89.

Head K, Chong LY, Hopkins C, Philpott C, Schilder AGM, Burton MJ. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011992

90.

Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 2020;10:1

91.

Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep 2014;14:441

92.

Umbreit C, Virchow JC, Thorn C, Hörmann K, Klimek L, Pfaar O. Analgetikaintoleranz. Ein häufiges, interdisziplinäres Krankheitsbild. Aspirin-Intolerance-Syndrom. A common and interdisciplinary disease. Internist 2010;51:1196

93.

Weber R, Trautmann A, Randerath W, Heppt W, Hosemann W. ASS-Toleranzinduktion. Therapieoption bei Patienten mit analgetikainduzierter Erkrankung der Atemwege. Aspirin desensitization. Therapy options in patients with aspirin-exacerbated respiratory disease / CME-FRagebogen. Questionnaire. HNO 2012;60:369-83

94.

Comert S, Celebioglu E, Yucel T, Erdogan T, Karakaya G, Onerci M et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy 2013;68:1443-51

95.

Fruth K, Pogorzelski B, Schmidtmann I, Springer J, Fennan N, Fraessdorf N et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 2013;68:659-65

96.

Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008;63:1228-34

97.

Havel M, Ertl L, Braunschweig F, Markmann S, Leunig A, Gamarra F et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol 2013;270:571-8

98.

Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-64

99.

Rizk H. Role of aspirin desensitization in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2011;19:210-7

100.

Renjiao L, Fengming L. The safety and efficacy of aspirin desensitization combined with long-term aspirin therapy in Aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2020;30:327-33

101.

A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps (SINUS-24) [database on the Internet]. Sanofi 2019. Accessed: 9.3.2020

102.

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52) [database on the Internet]. Sanofi. 2019. Accessed: 9.3.2020

103.

Mepolizumab in Nasal Polyposis. [database on the Internet] 2018. Accessed: 9.3.2020

104.

Effect of Mepolizumab in Severe Bilateral Nasal Polyps - EudraCT 2016-004255-70 [database on the Internet] 2019. Accessed: 9.3.2020

105.

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2) [database on the Internet]2019. Accessed: 9.3.2020

106.

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1) [database on the Internet]2019. Accessed: 9.3.2020

107.

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (OSTRO) [database on the Internet]. AstraZeneca. 2019. Accessed: 9.3.2020

108.

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) (ORCHID) [database on the Internet]. AstraZeneca. 2020. Accessed: 9.3.2020

109.

Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM et al. Humanization of an antibody directed against IgE. Journal of immunology (Baltimore, Md : 1950). 1993;151:2623-32

110.

MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45

111.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90

112.

Novartis_Pharma_GmbH. Xolair ^® 150 mg Injektionslösung, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt 2019:p. 9.

113.

Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bülbül Baskan E, Bradley MS et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:67-75

114.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6.e1

115.

Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014;134:560-7.e4.

116.

Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology 2020;58:226-32

117.

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394(10209):1638-50

118.

Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. Jama 2016;315:469-79

119.

GlaxoSmithKline_GmbH_&_Co._KG. Nucala 100 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2019: p. 6.

120.

Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol 2017;140:1024-31.e14

121.

AstraZeneca_GmbH. Fasenra ^® 30 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH- Fachinformation. Rote Liste Service GmbH Frankfurt. 2019 p. 7

122.

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis [database on the Internet]2019. Accessed: 9.3.2020

123.

Center HCaR. NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab (NAPPREB). 2019; https://clinicaltrials.gov/ct2/show/NCT04185012?term=NCT04185012&draw=2&rank=1.. Accessed 9.1.2020

124.

Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133-41

125.

Teva_B._V. Cinqaero 10mg/ml, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2018.

126.

Jacobs JS. Effect of Reslizumab in Chronic Rhinosinusitis. https://clinicaltrials.gov/ct2/show/NCT02799446?term=NCT02799446&draw=2&rank=1. 2018. Accessed 9.1.2020.

127.

Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020;75:148-57

128.

Liu T, Li TL, Zhao F, Xie C, Liu AM, Chen X et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. The American journal of the medical sciences. 2011;341:40-7

129.

Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, Yagi T et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res 2011;3:186-93

130.

Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013;132:593-600 e12

131.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014;44:29-37

132.

Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102-10

133.

Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012;135:327-36

134.

Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014-20

135.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-73

136.

Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 2020;104:776-9

137.

Klimek L, Koennecke M, Hagemann J, Wollenberg B, Becker S. [Immunology of chronic rhinosinusitis with nasal polyps as a basis for treatment with biologicals]. HNO 2019;67:15-26

138.

De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017;7:22

139.

Bachert C, Gevaert P, Hellings P. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol Pract 2017;5:1512-6

140.

Kim DW, Cho SH. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res 2017;9:299-306

141.

Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74:2312-9

142.

Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131-42

143.

Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC). Allergo J Int 2017;26:16-24

Titel: Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem
Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC)
verfasst von: Prof. Dr. med. Ludger Klimek
Ulrike Förster-Ruhrmann
PD Dr. med. Sven Becker
Dr. med. Adam M. Chaker
Sebastian Strieth
Thomas K. Hoffmann
Prof. Dr. med. Stefan Dazert
Thomas Deitmer
Heidi Olze
Alexander Glien
Prof. Dr. med. Stefan Plontke
Holger Wrede
Prof. Dr. med. Wolfgang W. Schlenter
Hans-Jürgen Welkoborsky
Barbara Wollenberg
Achim G. Beule
Claudia Rudack
Prof. Dr. med. Martin Wagenmann
Prof. Dr. Timo Stöver
Tilman Huppertz
Dr. med. Jan Hagemann
Prof. Dr. med. Claus Bachert
Publikationsdatum: 24.09.2021
Verlag: Springer Medizin
Schlagwörter: Asthma bronchiale
Allergologie in der HNO-Heilkunde
Omalizumab
Mepolizumab
Reslizumab
Rhinosinusitis
Dupilumab
Erschienen in: Allergo Journal / Ausgabe 6/2021
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI: https://doi.org/10.1007/s15007-021-4872-z

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem

Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC)

Auszug

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Step by Step: Online-Archiv, ePaper und CME-Fortbildung

Parfümierte Kosmetik sparsam einsetzen!

Allergene Pollen - auch ein Problem von Innenräumen?

Nutzung telemedizinischer Anwendungen durch niedergelassene Allergologen vor und während der SARS-CoV-2-Pandemie

Klimawandel auf allen Ebenen

Allergisches Asthma bronchiale

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie